The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
iBio intellectual property vice-president Dr Wayne Fitzmaurice noted that the invention covered by this patent enables increased efficiency in the expression of a range of commercially important proteins.
Stemulate provides researchers and cell therapy companies a cell expansion alternative to fetal bovine serum. Stemulate supports the expansion of multiple types of cells in vitro, including endothelial
Breakthroughs in American CryoStem’s proprietary cell culture medium (ACSelerate) and culturing methodology have enabled the Company to accelerate the robust cellular expansion and rapid differentiation of ADSCs to
The study, titled "Broadly neutralizing HIV antibodies define a novel glycan-dependent epitope on the pre-fusion conformation of gp41 on cleaved envelope trimers," describes a set of recently isolated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
